172 related articles for article (PubMed ID: 33029053)
1. De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.
Tiwari A; Saigal S; Choudhary NS; Saha S; Rastogi A; Bhangui P; Saraf N; Srinivasan T; Yadav SK; Gautam D; Nundy S; Soin AS
J Clin Exp Hepatol; 2020; 10(5):448-452. PubMed ID: 33029053
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of De Novo Malignancies After Living-Donor Liver Transplantation: A Single-Center Experience.
Wahab MA; Abdel-Khalek EE; Elshoubary M; Yassen AM; Salah T; Sultan AM; Fathy O; Elmorshedi M; Shiha U; Elsadany M; Adly R; Samy M; Shehta A
Transplant Proc; 2021 Mar; 53(2):636-644. PubMed ID: 33549346
[TBL] [Abstract][Full Text] [Related]
3. De Novo Malignancy Following Adult-to-Adult Living Donor Liver Transplantation Focusing on Posttransplantation Lymphoproliferative Disorder.
Mizuno S; Hayasaki A; Ito T; Fujii T; Iizawa Y; Kato H; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Usui M; Sakurai H; Isaji S
Transplant Proc; 2018 Nov; 50(9):2699-2704. PubMed ID: 30401380
[TBL] [Abstract][Full Text] [Related]
4. De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study.
Kaneko J; Sugawara Y; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Yamashiki N; Kokudo N
Transplantation; 2013 May; 95(9):1142-7. PubMed ID: 23572128
[TBL] [Abstract][Full Text] [Related]
5. De novo malignancies after liver transplantation: a single-center experience.
Hegab B; Khalaf H; Allam N; Azzam A; Al Khail FA; Al-hamoudi W; Kamel Y; Al Bahili H; Al Sofayan M; Al-Sebayel M
Ann Saudi Med; 2012; 32(4):355-8. PubMed ID: 22705604
[TBL] [Abstract][Full Text] [Related]
6. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
7. De Novo Malignancy After Adult-to-Adult Living Donor Liver Transplantation: A Single-Center Long-Term Experience.
Masuda Y; Mita A; Ohno Y; Kubota K; Notake T; Shimizu A; Soejima Y
Transplant Proc; 2023 May; 55(4):952-955. PubMed ID: 37088616
[TBL] [Abstract][Full Text] [Related]
8. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
[TBL] [Abstract][Full Text] [Related]
9. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
[TBL] [Abstract][Full Text] [Related]
10. Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center.
Kang SH; Hwang S; Ha TY; Song GW; Jung DH; Ahn CS; Moon DB; Kim KH; Park GC; Yoon YI; Park YH; Cho HD; Kwon JH; Chung YK; Choi JU; Lee SG
Korean J Transplant; 2019 Dec; 33(4):98-105. PubMed ID: 35769980
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
Altieri M; Sérée O; Lobbedez T; Segol P; Abergel A; Blaizot X; Boillot O; Boudjema K; Coilly A; Conti F; Chazouillères O; Debette-Gratien M; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Kamar N; Latournerie M; Lebray P; Leroy V; Neau-Cransac M; Pageaux GP; Radenne S; Salamé E; Saliba F; Samuel D; Vanlemmens C; Besch C; Launoy G; Dumortier J
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101514. PubMed ID: 33714907
[TBL] [Abstract][Full Text] [Related]
12. De novo malignancy after liver transplantation: a single-center experience of 14 cases.
Gao PJ; Gao J; Li Z; Hu ZP; Zhu JY
Ann Surg Treat Res; 2015 Apr; 88(4):222-8. PubMed ID: 25844357
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
[TBL] [Abstract][Full Text] [Related]
14. The incidence and risk factors of de novo skin cancer in the liver transplant recipients.
Modaresi Esfeh J; Hanouneh IA; Dalal D; Tabba A; Lopez R; Pagadala M; Eghtesad B; Zein NN
Int J Organ Transplant Med; 2012; 3(4):157-63. PubMed ID: 25013641
[TBL] [Abstract][Full Text] [Related]
15. Malignancy After Living Donor Liver Transplantation.
Kobayashi T; Miura K; Ishikawa H; Sakata J; Takizawa K; Hirose Y; Toge K; Saito S; Abe S; Kawachi Y; Ichikawa H; Shimada Y; Takahashi Y; Wakai T; Kinoshita Y
Transplant Proc; 2024 Apr; 56(3):660-666. PubMed ID: 38519268
[TBL] [Abstract][Full Text] [Related]
16. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
17. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
[TBL] [Abstract][Full Text] [Related]
19. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.
Jain AB; Yee LD; Nalesnik MA; Youk A; Marsh G; Reyes J; Zak M; Rakela J; Irish W; Fung JJ
Transplantation; 1998 Nov; 66(9):1193-200. PubMed ID: 9825817
[TBL] [Abstract][Full Text] [Related]
20. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
Bhat M; Mara K; Dierkhising R; Watt KD
Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
